Memantine

Memantine is an uncompetitive, low-to-moderate affinity N-methyl-D-aspartate (NMDA) glutamate receptor antagonist with pronounced voltage-dependency and fast channel-blocking kinetics. The drug enters the NMDA receptor-associated ion channel in its open state, occupying a binding site that overlaps with the physiological magnesium (Mg2+) site within the channel pore, thereby reducing cationic flux — particularly calcium — during sustained receptor activation.

The critical selectivity of memantine derives from its kinetic profile. Under normal synaptic conditions, glutamate is released in brief, high-concentration pulses producing transient strong depolarizations. Memantine's fast unblocking kinetics allow it to exit the channel rapidly during these events, preserving the calcium-dependent signaling required for long-term potentiation and memory consolidation.

In neurodegenerative disease, tonic low-level ambient glutamate persistently activates extrasynaptic NMDA receptors, generating sustained calcium influx that overwhelms cellular buffering capacity and triggers apoptotic and necrotic cascades — a process known as excitotoxicity. Memantine preferentially remains trapped in the channel during these chronic low-amplitude depolarizations, attenuating pro-death signaling while leaving phasic synaptic events largely intact. This selectivity for extrasynaptic versus synaptic NMDA receptor populations is the mechanistic basis for its neuroprotective profile. Memantine remains the only NMDA receptor antagonist to have cleared Phase III clinical trials and achieved commercial regulatory approval, a distinction attributed to this kinetic selectivity that earlier, higher-affinity NMDA blockers (such as phencyclidine) lacked.

Memantine received FDA approval in October 2003 for moderate-to-severe Alzheimer's disease (AD), supported by three randomized, double-blind, placebo-controlled trials submitted in its New Drug Application.

The pivotal Reisberg 2003 trial (study identifier MRZ-9605; n=252, 28 weeks; MMSE 3-14) demonstrated statistically significant superiority over placebo on the Alzheimer's Disease Cooperative Study Activities of Daily Living scale (ADCS-ADL, mean difference 3.4 units, p=0.02) and the Severe Impairment Battery (SIB, mean difference 5.7 units, p<0.001). Responder analysis found 29% of memantine-treated patients versus 10% of placebo patients met clinical response criteria.

The Tariot 2004 trial (MEM-MD-02; n=404, 24 weeks) examined memantine added to stable donepezil therapy and found significant improvements over placebo across all co-primary and key secondary endpoints: ADCS-ADL (p=0.03), SIB (p<0.01), CIBIC-Plus global impression (p=0.03), and Neuropsychiatric Inventory (p=0.002).

A 2015 PLOS One meta-analysis of 9 RCTs (n=2,433 patients) confirmed statistically significant effects of memantine monotherapy but characterized them as clinically small: cognition (SMD -0.27, 95% CI -0.39 to -0.14), global function (SMD -0.18), and behavioral disturbances (SMD -0.12). The authors concluded that despite statistical significance across multiple domains, the magnitude of clinical benefit was limited.

The 2012 NEJM randomized trial by Howard et al. (n=295) found that memantine alone produced modest cognitive gains of 1.2 points on the Standardized MMSE, and the combination of memantine plus donepezil showed no statistically significant advantage over donepezil monotherapy on the study's co-primary endpoints.

Evidence for benefit in mild-to-moderate AD (MMSE 14-24) is inconsistent; most RCTs in this population failed to meet their predefined 24-week primary endpoints. Off-label applications in psychiatric conditions — OCD, ADHD, depression, bipolar disorder, schizophrenia — have been examined in small trials, but a 2025 review of 23 studies (9 RCTs) concluded the evidence base per disorder remains very limited and larger RCTs are needed.

Typical dosage: 5-20 mg (daily).

Memantine is available in three formulations in the United States: immediate-release (IR) tablets (5 mg, 10 mg), extended-release (ER) capsules (7, 14, 21, 28 mg), and oral solution (2 mg/mL).

Immediate-release titration per FDA prescribing information: • Week 1: 5 mg once daily • Week 2: 10 mg/day (5 mg twice daily) • Week 3: 15 mg/day (5 mg morning, 10 mg evening) • Week 4 onward: 20 mg/day (10 mg twice daily; target maintenance dose) The minimum recommended interval between dose increments is one week. Maximum recommended dose is 20 mg per day.

Extended-release: Begin at 7 mg once daily; increase in 7 mg weekly increments, tolerability permitting, to a maximum of 28 mg once daily.

Renal dose adjustment: In severe renal impairment (CrCl 5-29 mL/min), target dose should not exceed 5 mg twice daily for the IR formulation. No adjustment is required for mild-to-moderate renal impairment or moderate hepatic impairment. Area under the curve increases 4-115% with declining renal function, reflecting the drug's 48% urinary excretion unchanged.

Pharmacokinetics: Peak plasma concentration occurs 9-12 hours after oral dosing; half-life is 60-80 hours; CYP450 metabolism is minimal. Urine alkalinization to pH 8 can reduce renal clearance by approximately 80%, potentially causing drug accumulation.

This information is provided for educational purposes only and does not constitute medical advice. Memantine is a prescription medication; dosing must be determined and supervised by a licensed healthcare provider.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The best-evidenced combination is memantine plus a cholinesterase inhibitor, most commonly donepezil, which the FDA recognizes as an approved combination for moderate-to-severe AD. The mechanistic rationale is complementarity: memantine attenuates glutamatergic excitotoxicity while acetylcholinesterase inhibitors (AChEIs) amplify cholinergic transmission, targeting two distinct but functionally interconnected pathways. Glutamatergic neurons synapse onto cholinergic neurons in the basal forebrain whose projections innervate memory-critical cortical and hippocampal regions. The Tariot 2004 RCT provided randomized evidence of multi-domain benefit for this combination; however, the 2012 NEJM trial by Howard et al. found no significant advantage of combination over donepezil monotherapy alone on co-primary cognitive and functional endpoints, illustrating that clinical evidence is mixed.

Off-label combinations reported in limited trials: • Memantine plus fluvoxamine for OCD: a small 2013 randomized trial showed significant symptom improvement when memantine (10 mg twice daily) was added to fluvoxamine; independent replication is lacking. • Memantine with stimulants or atomoxetine for ADHD: explored in open-label studies only; evidence is anecdotal with modest effect sizes reported. • Memantine with antipsychotics for cognitive deficits in schizophrenia: examined in small trials with mixed results and no consensus. • Combination with racetams or ampakines in the nootropic community: anecdotal only; no controlled clinical evidence exists.

Memantine is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Dizziness, headache possible

In pivotal placebo-controlled trials, the treatment-discontinuation rate due to adverse events was nearly identical between the memantine (10.1%) and placebo (11.5%) groups, indicating that adverse events rarely necessitated treatment cessation and reflecting an overall favorable tolerability profile.

Adverse reactions occurring in at least 5% of patients and at higher rates than placebo: • Dizziness (7% vs 5% placebo) • Headache (6% vs 3%) • Confusion (6% vs 5%) • Constipation (5% vs 3%)

Additional reactions occurring in at least 2% of treated patients include hypertension (4% vs 2%), vomiting (3% vs 2%), hallucinations (3% vs 2%), somnolence (3% vs 2%), back pain (3% vs 2%), and dyspnea (2% vs 1%). Seizures occurred in 0.2% of memantine-treated patients versus 0.5% in the placebo group.

Rare but serious adverse events reported post-marketing include neuroleptic malignant syndrome, Stevens-Johnson syndrome, hepatitis and liver failure, and cardiovascular events including heart failure and myocardial infarction.

Contraindications: Hypersensitivity to memantine hydrochloride or any formulation excipient.

Drug interactions: Urine-alkalizing agents (carbonic anhydrase inhibitors, sodium bicarbonate) can reduce memantine renal clearance by approximately 80% at urinary pH 8, risking drug accumulation and toxicity. Combined use with other NMDA antagonists (amantadine, ketamine, dextromethorphan) has not been systematically evaluated and may increase neuropsychiatric adverse effects. Drugs sharing the renal cation transport system (cimetidine, ranitidine, quinidine, metformin, hydrochlorothiazide, triamterene, nicotine) may alter memantine plasma concentrations. No pharmacokinetic interaction was observed between memantine and donepezil in clinical studies.

Severe renal impairment requires dose reduction. Memantine is Pregnancy Category B; animal studies at high doses showed reduced fetal skeletal ossification, and human data are insufficient. Pediatric safety and efficacy have not been established.